Rigel Q3 EPS Misses at $0.65 as Launch Costs Weigh, Revenue Tops Estimates
RIGL sits 76% above its 52-week low of $24.95 on elevated volume (2.2× avg).
Summary
Rigel posted Q3 adjusted EPS of $0.65, well below the $0.84 consensus and down from $1.46 a year ago. Revenue rose 16.5% to $80.89 million, edging past the $80.10 million analysts expected, and included $6.6 million of first VEPPANU sales. Net income fell to $13.19 million from $27.9 million, reflecting launch costs and the absence of last year's one-time Lilly gain. The top line held up but the profit miss is the story — the stock closed at $51.29 and the median analyst target is $55.00.
At the time of this announcement, RIGL was trading at $43.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $853.9M. The 52-week trading range was $24.95 to $52.61. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.